227 related articles for article (PubMed ID: 26813676)
1. Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.
Bellon M; Lu L; Nicot C
Blood; 2016 May; 127(20):2439-50. PubMed ID: 26813676
[TBL] [Abstract][Full Text] [Related]
2. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
4. JAG1 overexpression contributes to Notch1 signaling and the migration of HTLV-1-transformed ATL cells.
Bellon M; Moles R; Chaib-Mezrag H; Pancewicz J; Nicot C
J Hematol Oncol; 2018 Sep; 11(1):119. PubMed ID: 30231940
[TBL] [Abstract][Full Text] [Related]
5. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
[TBL] [Abstract][Full Text] [Related]
6. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
[TBL] [Abstract][Full Text] [Related]
7. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
Yadav AK; Kumar V; Bailey DB; Jang BC
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
[TBL] [Abstract][Full Text] [Related]
8. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
9. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells.
Cheng J; Zhang D; Zhou C; Marasco WA
Leuk Res; 2004 Jan; 28(1):71-82. PubMed ID: 14630083
[TBL] [Abstract][Full Text] [Related]
11. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
Tomita M; Kawakami H; Uchihara JN; Okudaira T; Masuda M; Matsuda T; Tanaka Y; Ohshiro K; Mori N
Retrovirology; 2006 Apr; 3():22. PubMed ID: 16603085
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
Narita T; Ishida T; Ito A; Masaki A; Kinoshita S; Suzuki S; Takino H; Yoshida T; Ri M; Kusumoto S; Komatsu H; Imada K; Tanaka Y; Takaori-Kondo A; Inagaki H; Scholz A; Lienau P; Kuroda T; Ueda R; Iida S
Blood; 2017 Aug; 130(9):1114-1124. PubMed ID: 28646117
[TBL] [Abstract][Full Text] [Related]
14. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PIM1 kinase attenuates inflammation-induced pro-labour mediators in human foetal membranes in vitro.
Lim R; Barker G; Lappas M
Mol Hum Reprod; 2017 Jun; 23(6):428-440. PubMed ID: 28333279
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis.
Remy J; Linder B; Weirauch U; Konovalova J; Marschalek R; Aigner A; Kögel D
Biochim Biophys Acta Mol Cell Res; 2019 Feb; 1866(2):175-189. PubMed ID: 30389373
[TBL] [Abstract][Full Text] [Related]
17. Impaired expression of DICER and some microRNAs in HBZ expressing cells from acute adult T-cell leukemia patients.
Gazon H; Belrose G; Terol M; Meniane JC; Mesnard JM; Césaire R; Peloponese JM
Oncotarget; 2016 May; 7(21):30258-75. PubMed ID: 26849145
[TBL] [Abstract][Full Text] [Related]
18. STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I-Transformed and ATL Cells.
Moles R; Bellon M; Nicot C
Neoplasia; 2015 May; 17(5):449-62. PubMed ID: 26025667
[TBL] [Abstract][Full Text] [Related]
19. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.
Watanabe T; Yamashita S; Ureshino H; Kamachi K; Kurahashi Y; Fukuda-Kurahashi Y; Yoshida N; Hattori N; Nakamura H; Sato A; Kawaguchi A; Sueoka-Aragane N; Kojima K; Okada S; Ushijima T; Kimura S; Sueoka E
Blood; 2020 Aug; 136(7):871-884. PubMed ID: 32391874
[TBL] [Abstract][Full Text] [Related]
20. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
